CHLORPROMAZINE showed no clear difference in leaving the study early ‐ due to adverse effects (short term) compared with RESERPINE (moderate certainty).
CHLORPROMAZINE showed no clear difference in behaviour: Not improved ‐ general (medium term) compared with RESERPINE (moderate certainty).
It is very uncertain whether CHLORPROMAZINE changes relapse compared with PLACEBO (very low certainty).
It is very uncertain whether CHLORPROMAZINE changes global state: no overall improvement (psychiatrist ‐ rated) compared with PLACEBO (very low certainty).
CHLORPROMAZINE may leads to lower leaving the study early compared with PLACEBO (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether CHLORPROMAZINE changes behaviour: deteriorated/ disturbed/un‐cooperative compared with PLACEBO (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether CHLORPROMAZINE changes global outcome: Number of additional injections ‐ 2‐4 injections compared with HALOPERIDOL (very low certainty).
It is very uncertain whether CHLORPROMAZINE changes global outcome: Number of additional injections ‐ 5 or more compared with HALOPERIDOL (very low certainty).
It is very uncertain whether CHLORPROMAZINE changes adverse effects ‐ cardiovascular ‐ hypotension compared with HALOPERIDOL (very low certainty).
It is very uncertain whether CHLORPROMAZINE changes adverse effects ‐ seizures compared with HALOPERIDOL (very low certainty).
It is very uncertain whether CHLORPROMAZINE changes leaving the study early compared with HALOPERIDOL (very low certainty).
It is very uncertain whether CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) changes global state: no improvement ‐ short term compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (very low certainty).
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower leaving the study early ‐ any reason compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) may leads to higher behaviour: deterioration of behaviour (categorised as reason to… compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (low certainty).